Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ijcp.14752 http://scihub22266oqcxt.onion/10.1111/ijcp.14752 34431178!8646897!34431178     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Clin+Pract 2021 ; 75 (11): e14752 Nephropedia Template TP {{tp|p=34431178|t=2021. Can treatment with teicoplanin improve the prognosis of COVID-19 patients?|pdf=|usr=}}{{34431178}} gab.com Text Can treatment with teicoplanin improve the prognosis of COVID-19 patients JO: Int J Clin Pract http://www.kidney.de/pget.php?&tw=1&pmid=34431178 #FOAvip AIM: In patients with COVID-19, no validated efficient treatment has been reported. Herein, we examine the effect of treatment with teicoplanin in hospitalised patients with COVID-19. METHODS: This retrospective study included 115 hospitalised patients in one medical centre. Fifty-four patients with laboratory-confirmed COVID-19 who received teicoplanin plus standard care were included in the Teicoplanin arm of this study, whereas 61 patients who were treated with standard care (SC) according to the Turkish Health Organization guidelines were included in the control arm. Patients' baseline characteristics, clinical presentation, treatment and outcomes were compared between the two groups. RESULTS: In this non-randomised control study, all baseline characteristics were comparable between the two arms and there were no significant differences in the presenting symptoms, comorbidities and clinical outcomes between the two groups. However, the mortality rate was significantly lower in the teicoplanin group than in the control group (1.9% vs 14.8%; P < .05). In addition, no adverse reactions were found in the teicoplanin arm. CONCLUSIONS: Teicoplanin administration is associated significantly with lower mortality in hospitalised patients with COVID-19 in our study. Further clinical investigations is required to verify the role of teicoplanin in COVID-19 patients. Twit Text FOAVip Can treatment with teicoplanin improve the prognosis of COVID-19 patients ????Int J Clin Pract http://www.kidney.de/pget.php?&tw=1&pmid=34431178 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34431178 #FOAvip English Wikipedia <ref>{{Cite pmid|34431178}}</ref> Can treatment with teicoplanin improve the prognosis of COVID-19 patients? #MMPMID34431178 Yasar Z; Yemisen M; Yasar H; Ertas A; Meric K; Sahin S Int J Clin Pract 2021[Nov]; 75 (11): e14752 PMID34431178show ga AIM: In patients with COVID-19, no validated efficient treatment has been reported. Herein, we examine the effect of treatment with teicoplanin in hospitalised patients with COVID-19. METHODS: This retrospective study included 115 hospitalised patients in one medical centre. Fifty-four patients with laboratory-confirmed COVID-19 who received teicoplanin plus standard care were included in the Teicoplanin arm of this study, whereas 61 patients who were treated with standard care (SC) according to the Turkish Health Organization guidelines were included in the control arm. Patients' baseline characteristics, clinical presentation, treatment and outcomes were compared between the two groups. RESULTS: In this non-randomised control study, all baseline characteristics were comparable between the two arms and there were no significant differences in the presenting symptoms, comorbidities and clinical outcomes between the two groups. However, the mortality rate was significantly lower in the teicoplanin group than in the control group (1.9% vs 14.8%; P < .05). In addition, no adverse reactions were found in the teicoplanin arm. CONCLUSIONS: Teicoplanin administration is associated significantly with lower mortality in hospitalised patients with COVID-19 in our study. Further clinical investigations is required to verify the role of teicoplanin in COVID-19 patients. |*COVID-19[MESH] |*Teicoplanin/therapeutic use[MESH] |Humans[MESH] |Prognosis[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]Can treatment with teicoplanin improve the prognosis of COVID-19 patie(epmc).pdf DeepDyve Pubget Overpricing